DanielLMulkerinMD(He/Him)

Oncology • Rochester, NY

Gastrointestinal Cancer, Hematologic Oncology

Associate Director for Regional Cancer Operations, Wilmot Cancer Institute Vice Chair Regional Operations, Dept. of Medicine, University of Rochester

Join to view full profile

Dr. Mulkerin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mulkerin's full profile

Already have an account?

Office
601 Elmwood Ave
Rochester, NY 14642
Phone+1 585-275-5823

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1996 - 1999
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1992 - 1996
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1992

Certifications & Licensure

NY State Medical License 2021 - 2026
WI State Medical License 1993 - 2025
IL State Medical License 2014 - 2017
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction Start of enrollment: 2003 Jan 01
Completed
Phase 1
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 2
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Start of enrollment: 2007 Feb 28
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

69 citations
A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma
Tabraiz A. Mohammed, Kyle D. Holen, Renata Jaskula-Sztul, Daniel Mulkerin, Sam J. Lubner
The Oncologist. 2011-06-01
608 citations
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: ...
Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Briant Fruth
JAMA. 2017-06-20
1 citations
Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care.
Randall F. Holcombe, Claire F. Verschraegen, Andrew E. Chapman, David K. Gaffney, Richard M. Goldberg
Journal of the National Comprehensive Cancer Network. 2021-02-02

Press Mentions

Wilmot Cancer Institute Brings Multidisciplinary Cancer Care to WebsterJuly 7th, 2022